These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34213048)

  • 1. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study.
    Chen PD; Chen LJ; Chang YJ; Chang YJ
    Oncologist; 2021 Oct; 26(10):e1774-e1785. PubMed ID: 34213048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
    Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
    Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
    Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
    Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
    Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
    Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors.
    Jarnagin WR; Weber S; Tickoo SK; Koea JB; Obiekwe S; Fong Y; DeMatteo RP; Blumgart LH; Klimstra D
    Cancer; 2002 Apr; 94(7):2040-6. PubMed ID: 11932907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
    Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
    Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.
    Sapisochin G; de Lope CR; Gastaca M; de Urbina JO; López-Andujar R; Palacios F; Ramos E; Fabregat J; Castroagudín JF; Varo E; Pons JA; Parrilla P; González-Diéguez ML; Rodriguez M; Otero A; Vazquez MA; Zozaya G; Herrero JI; Antolin GS; Perez B; Ciria R; Rufian S; Fundora Y; Ferron JA; Guiberteau A; Blanco G; Varona MA; Barrera MA; Suarez MA; Santoyo J; Bruix J; Charco R
    Ann Surg; 2014 May; 259(5):944-52. PubMed ID: 24441817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.
    Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS
    BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
    Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
    PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis.
    Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH
    BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma].
    Kim W; Lee JH; Kim YJ; Yoon JH; Suh KS; Lee KU; Jang JJ; Lee HS
    Korean J Gastroenterol; 2007 Mar; 49(3):158-65. PubMed ID: 18172344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
    Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
    World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
    Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
    Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma.
    Holzner ML; Tabrizian P; Parvin-Nejad FP; Fei K; Gunasekaran G; Rocha C; Facciuto ME; Florman S; Schwartz ME
    Liver Transpl; 2020 Jul; 26(7):888-898. PubMed ID: 32352208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
    Hayashi H; Beppu T; Ishiko T; Mizumoto T; Masuda T; Okabe K; Baba Y; Okabe H; Takamori H; Kanemitsu K; Hiroto M; Baba H
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1941-3. PubMed ID: 17212153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.
    Garancini M; Goffredo P; Pagni F; Romano F; Roman S; Sosa JA; Giardini V
    Liver Transpl; 2014 Aug; 20(8):952-9. PubMed ID: 24777610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
    Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
    Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.